Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment;Efficacité de l'interféron alpha dans le traitement des œdmes maculaires uvéitiques réfractaires au traitement corticoïde et/ou immunosupresseur

Journal Francais d'Ophtalmologie

Volumn 33, Issue 3, 2010, Pages 152-162

  Paire, V ^a   Lebreton, O ^a   Weber, M ^a  

^a HÔTEL DIEU   (France)

Author keywords

Interferon; Macular edema; Uveitis

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE REPORT; CHORIORETINITIS; DRUG RESISTANCE; FEMALE; GLAUCOMA; HUMAN; INTERMEDIATE UVEITIS; MALE; MIDDLE AGED; RECURRENT DISEASE; RETINA MACULA EDEMA; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CHORIORETINITIS; DRUG RESISTANCE; FEMALE; GLAUCOMA; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; MACULAR EDEMA; MALE; MIDDLE AGED; RECURRENCE; UVEITIS, INTERMEDIATE; UVEITIS, POSTERIOR; VISUAL ACUITY; YOUNG ADULT;

EID: 77949655425     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2010.01.008     Document Type: Article

References (37)

1. Tessler HH, Pepose JS, Wilhelmus KR. Cystoid macular edema In: Ocular infection and immunity. Mosby 1996:p.553-559
2. Hikichi T, Trempe CL. Role of the vitreous in the prognosis of peripherical uveitis. Am J Ophthalmol 1993;116:401-405
3. Kent D, Vinores SA, Campochiaro PA. Macular edema: The role of soluble mediators. Br J Ophthalmol 2000;84:542-545
4. Brasseur G, Weber M. Vitré et inflammation. In: Pathologie du vitré Masson, Paris 2003:315-337
5. Gordon DM. Prednisone and prednisolone in ocular disease. Am J Ophthalmol 1956;41:593-600.
6. Lindstedt EW, BaarsamaG, Kuijpers RW, Van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-536
7. Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: Treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278:335-336
8. Feron EJ, Rothova A, Van Hagen PM, Baarsma GS, Suttorp- Schulten MS. Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 1994;344:33.
9. Sánchez Román J, Pulido Aquilera MC, Castillo Palma MJ, Ocaña Medina C, Toral Peña A, López-Checa F, et al. The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease). Rev Clin Exp 1996;196:293-298
10. Cogrel O, Doutre MS, Marlière V, Beylot-Barry M, Couzigou P, Beylot C. Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. Br J Dermatol 2002;146:320-324
11. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401-406
12. Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV. Interferon-alpha: A Key Factor in Autoimmune Disease? Invest Ophthalmol Vis Sci 2006;47:3946-3950
13. Brassard DL, Grace MJ, Bordens RW. Interferon alpha as an immunotherapeutic protein. J Leukoc Biol 2002;71:565-581
14. Dieperink E, Willenbring M, Samuel B. Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review. Am J Pyschiatry 2000;157:867-876
15. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Eng J Med 1989;321:1501-1506
16. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
17. Guyer DR, Tiedman J, Yannuzzi LA, Slakter JS, Parke D, Kelley J, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-356
18. D'Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006;44:56-61.
19. Stoffelns BM. Interferon causes ischemic ocular diseases-case studies and review of the literature. Klin Monatsbl Augenheilkd 2006;223:367-371
20. Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004;88:1518-1520
21. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:1692-1695
22. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61.
23. Bodaghi B, Gendron G,Wechsler B, Terrada C, Cassoux N, Huong du LT, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-339
24. Gastro-Entérologie SNFD. Texte de consensus sur le traitement de l'hépatite virale C. Gastroenterol Clin Biol 2002;26:303-311
25. Kötter I, Ziehut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-431
26. Guillaume-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology 2007;46:1570-1573
27. Cassoux N, Goichot-Bonnat L, Karmochkine M, Georges F, Kullmann N, Lehoang P, et al. Efficacité et tolérance des immunoglobulines intraveineuses dans le traitement de la rétinochoroïdopathie de type Birdshot. J Fr Ophtalmol 2002;25:23-30.
28. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96:275-282
29. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalomology 2005;112:1006-1071
30. Towler HM, Cliffe AM, Whiting PH, Forrester JV. Lowdose cyclosporin A therapy in chronic posterior uveitis. Eye 1989;3:282-287
31. Deuter CM, Koestter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: A new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006;26:786-791
32. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001;29: 2-6.
33. Lang Y, Zemel E, Miller B, Perlman I. Retinal toxicity of intravitreal kenalog in albino rabbits. Retina 2007;27: 778-788
34. Baath J, Ells AL, Crichton A, Kherani A,Williams RG. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007;23:304-310
35. Galor A, Margolis R, Brasil OM, Perez VL, Kaiser PK, Sears JE, Lowder CY, Smith SD. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology 2007;114:1912-1918
36. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-1579
37. Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of adamantiades-Behcet's disease. Curr Opin Rheumatol 2006;18:3-9.